Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 321

1.

Illegal cannabis use is common among Danes with multiple sclerosis.

Gustavsen S, Søndergaard HB, Andresen SR, Magyari M, Sørensen PS, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2019 Aug;33:5-12. doi: 10.1016/j.msard.2019.05.008. Epub 2019 May 16.

PMID:
31129415
2.

Worsening of disability caused by relapses in multiple sclerosis: A different approach.

Koch-Henriksen N, Thygesen LC, Sørensen PS, Magyari M.

Mult Scler Relat Disord. 2019 Jul;32:1-8. doi: 10.1016/j.msard.2019.04.017. Epub 2019 Apr 15.

PMID:
31003200
3.

Pulsed immune reconstitution therapy in multiple sclerosis.

Sorensen PS, Sellebjerg F.

Ther Adv Neurol Disord. 2019 Mar 28;12:1756286419836913. doi: 10.1177/1756286419836913. eCollection 2019. Review.

4.

The changing course of multiple sclerosis: rising incidence, change in geographic distribution, disease course, and prognosis.

Magyari M, Sorensen PS.

Curr Opin Neurol. 2019 Jun;32(3):320-326. doi: 10.1097/WCO.0000000000000695.

PMID:
30925518
5.

Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.

Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F.

Mult Scler Relat Disord. 2019 Apr;29:168-174. doi: 10.1016/j.msard.2019.01.038. Epub 2019 Jan 24.

6.

Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study.

Buron MD, Chalmer TA, Sellebjerg F, Frederiksen J, Góra MK, Illes Z, Kant M, Mezei Z, Petersen T, Rasmussen PV, Roshanisefat H, Hassanpour-Kalam-Roudy H, Sejbæk T, Tsakiri A, Weglewski A, Sorensen PS, Magyari M.

Neurology. 2019 Apr 16;92(16):e1811-e1820. doi: 10.1212/WNL.0000000000007314. Epub 2019 Mar 15.

PMID:
30877188
7.

Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.

Chalmer TA, Kalincik T, Laursen B, Sorensen PS, Magyari M; Members of Danish Multiple Sclerosis Group.

J Neurol. 2019 Feb;266(2):306-315. doi: 10.1007/s00415-018-9126-y. Epub 2018 Dec 4.

PMID:
30515628
8.

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.

Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, Sievers-Stober C, Lindberg RLP, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung HP, Comabella M, Montalban X, Derfuss T, Sellebjerg F, Dönnes P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium.

J Neuroimmunol. 2019 Jan 15;326:19-27. doi: 10.1016/j.jneuroim.2018.11.002. Epub 2018 Nov 7.

PMID:
30447419
9.

Early versus later treatment start in multiple sclerosis: a register-based cohort study.

Chalmer TA, Baggesen LM, Nørgaard M, Koch-Henriksen N, Magyari M, Sorensen PS; Danish Multiple Sclerosis Group.

Eur J Neurol. 2018 Oct;25(10):1262-e110. doi: 10.1111/ene.13692. Epub 2018 Jul 9.

PMID:
29847005
10.

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.

Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, Derosier FJ, Lopez MC, Kavanagh ST, Miller AE, Sorensen PS.

Neurology. 2018 May 15;90(20):e1805-e1814. doi: 10.1212/WNL.0000000000005516. Epub 2018 Apr 25. Erratum in: Neurology. 2018 Sep 11;91(11):538.

11.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20.

PMID:
29353550
12.

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Erratum in: Eur J Neurol. 2018 Mar;25(3):605.

PMID:
29352526
13.

Smoking affects the interferon beta treatment response in multiple sclerosis.

Petersen ER, Oturai AB, Koch-Henriksen N, Magyari M, Sørensen PS, Sellebjerg F, Søndergaard HB.

Neurology. 2018 Feb 13;90(7):e593-e600. doi: 10.1212/WNL.0000000000004949. Epub 2018 Jan 17.

PMID:
29343473
14.

Disability in progressive MS is associated with T2 lesion changes.

Ammitzbøll C, Dyrby TB, Lyksborg M, Schreiber K, Ratzer R, Romme Christensen J, Iversen P, Magyari M, Garde E, Sørensen PS, Siebner HR, Sellebjerg F.

Mult Scler Relat Disord. 2018 Feb;20:73-77. doi: 10.1016/j.msard.2017.12.010. Epub 2017 Dec 18.

PMID:
29324249
15.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
16.

Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.

Thormann A, Sørensen PS, Koch-Henriksen N, Laursen B, Magyari M.

Neurology. 2017 Oct 17;89(16):1668-1675. doi: 10.1212/WNL.0000000000004508. Epub 2017 Sep 20.

PMID:
28931645
17.

Chronic comorbidity in multiple sclerosis is associated with lower incomes and dissolved intimate relationships.

Thormann A, Sørensen PS, Koch-Henriksen N, Thygesen LC, Laursen B, Magyari M.

Eur J Neurol. 2017 Jun;24(6):825-834. doi: 10.1111/ene.13297.

PMID:
28544411
18.

Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.

Sørensen PS, Comi G, Vollmer TL, Montalban X, Kappos L, Dadon Y, Gorfine T, Margalit M, Sasson N, Rubinchick S, Knappertz V.

Int J MS Care. 2017 Jan-Feb;19(1):16-24. doi: 10.7224/1537-2073.2015-024.

19.

Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis.

Petersen ER, Søndergaard HB, Oturai AB, Jensen P, Sorensen PS, Sellebjerg F, Börnsen L.

Mult Scler Relat Disord. 2016 Nov;10:66-72. doi: 10.1016/j.msard.2016.09.001. Epub 2016 Sep 6.

PMID:
27919501
20.

Inverse comorbidity in multiple sclerosis: Findings in a complete nationwide cohort.

Thormann A, Koch-Henriksen N, Laursen B, Sørensen PS, Magyari M.

Mult Scler Relat Disord. 2016 Nov;10:181-186. doi: 10.1016/j.msard.2016.10.008. Epub 2016 Oct 29.

PMID:
27919487
21.

Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab.

Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2016 Nov;10:169-173. doi: 10.1016/j.msard.2016.10.005. Epub 2016 Oct 26.

PMID:
27919484
22.

Early safety and efficacy of fingolimod treatment in Denmark.

Voldsgaard A, Koch-Henriksen N, Magyari M, Sellebjerg F, Sørensen PS, Oturai AB.

Acta Neurol Scand. 2017 Jan;135(1):129-133. doi: 10.1111/ane.12573. Epub 2016 Mar 8.

PMID:
27910101
23.

The Danish Multiple Sclerosis Treatment Register.

Magyari M, Koch-Henriksen N, Sørensen PS.

Clin Epidemiol. 2016 Oct 25;8:549-552. eCollection 2016. Review.

24.

Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.

Thormann A, Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS.

J Neurol. 2016 Dec;263(12):2484-2493. Epub 2016 Oct 3.

PMID:
27699465
25.

Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedström A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Søndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, D'Alfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF.

Neurol Genet. 2016 Aug 4;2(4):e87. doi: 10.1212/NXG.0000000000000087. eCollection 2016 Aug.

26.

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.

Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202. eCollection 2016 Apr.

27.

Ozanimod: a better or just another S1P receptor modulator?

Sørensen PS.

Lancet Neurol. 2016 Apr;15(4):345-7. doi: 10.1016/S1474-4422(16)00041-7. Epub 2016 Feb 12. No abstract available. Erratum in: Lancet Neurol. 2016 Jun;15(7):656.

PMID:
26879277
28.

Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.

Sørensen PS, Sellebjerg F, Lycke J, Färkkilä M, Créange A, Lund CG, Schluep M, Frederiksen JL, Stenager E, Pfleger C, Garde E, Kinnunen E, Marhardt K; RECYCLINE Study Investigators.

Eur J Neurol. 2016 May;23(5):861-70. doi: 10.1111/ene.12953. Epub 2016 Feb 5.

PMID:
26848561
29.

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.

Sorensen PS, Blinkenberg M.

Ther Adv Neurol Disord. 2016 Jan;9(1):44-52. doi: 10.1177/1756285615601933. Review.

30.

Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.

Hermanrud C, Ryner M, Luft T, Jensen PE, Ingenhoven K, Rat D, Deisenhammer F, Sørensen PS, Pallardy M, Sikkema D, Bertotti E, Kramer D, Creeke P, Fogdell-Hahn A; ABIRISK Consortium.

J Immunol Methods. 2016 Mar;430:1-9. doi: 10.1016/j.jim.2016.01.004. Epub 2016 Jan 11.

PMID:
26779831
31.

Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis.

Dogonowski AM, Blinkenberg M, Paulson OB, Sellebjerg F, Sørensen PS, Siebner HR, Madsen KH.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):912-4. doi: 10.1136/jnnp-2015-311375. Epub 2015 Dec 14. No abstract available.

32.

Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?

Sørensen PS.

Nat Rev Neurol. 2016 Jan;12(1):5-6. doi: 10.1038/nrneurol.2015.224. Epub 2015 Dec 4.

PMID:
26635211
33.

Association between age at onset of multiple sclerosis and vitamin D level-related factors.

Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB.

Neurology. 2016 Jan 5;86(1):88-93. doi: 10.1212/WNL.0000000000002075. Epub 2015 Oct 7.

PMID:
26446064
34.

Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.

Ratzer R, Iversen P, Börnsen L, Dyrby TB, Romme Christensen J, Ammitzbøll C, Madsen CG, Garde E, Lyksborg M, Andersen B, Hyldstrup L, Sørensen PS, Siebner HR, Sellebjerg F.

Mult Scler. 2016 Jun;22(7):926-34. doi: 10.1177/1352458515605908. Epub 2015 Oct 2.

PMID:
26432857
35.

Physical and social environment and the risk of multiple sclerosis.

Magyari M, Koch-Henriksen N, Pfleger CC, Sørensen PS.

Mult Scler Relat Disord. 2014 Sep;3(5):600-6. doi: 10.1016/j.msard.2014.07.002. Epub 2014 Jul 21.

PMID:
26265272
36.

Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.

Taylor JC, Martin HC, Lise S, Broxholme J, Cazier JB, Rimmer A, Kanapin A, Lunter G, Fiddy S, Allan C, Aricescu AR, Attar M, Babbs C, Becq J, Beeson D, Bento C, Bignell P, Blair E, Buckle VJ, Bull K, Cais O, Cario H, Chapel H, Copley RR, Cornall R, Craft J, Dahan K, Davenport EE, Dendrou C, Devuyst O, Fenwick AL, Flint J, Fugger L, Gilbert RD, Goriely A, Green A, Greger IH, Grocock R, Gruszczyk AV, Hastings R, Hatton E, Higgs D, Hill A, Holmes C, Howard M, Hughes L, Humburg P, Johnson D, Karpe F, Kingsbury Z, Kini U, Knight JC, Krohn J, Lamble S, Langman C, Lonie L, Luck J, McCarthy D, McGowan SJ, McMullin MF, Miller KA, Murray L, Németh AH, Nesbit MA, Nutt D, Ormondroyd E, Oturai AB, Pagnamenta A, Patel SY, Percy M, Petousi N, Piazza P, Piret SE, Polanco-Echeverry G, Popitsch N, Powrie F, Pugh C, Quek L, Robbins PA, Robson K, Russo A, Sahgal N, van Schouwenburg PA, Schuh A, Silverman E, Simmons A, Sørensen PS, Sweeney E, Taylor J, Thakker RV, Tomlinson I, Trebes A, Twigg SR, Uhlig HH, Vyas P, Vyse T, Wall SA, Watkins H, Whyte MP, Witty L, Wright B, Yau C, Buck D, Humphray S, Ratcliffe PJ, Bell JI, Wilkie AO, Bentley D, Donnelly P, McVean G.

Nat Genet. 2015 Jul;47(7):717-726. doi: 10.1038/ng.3304. Epub 2015 May 18.

37.

Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis.

Börnsen L, Romme Christensen J, Ratzer R, Hedegaard C, Søndergaard HB, Krakauer M, Hesse D, Nielsen CH, Sorensen PS, Sellebjerg F.

PLoS One. 2015 Mar 4;10(3):e0118830. doi: 10.1371/journal.pone.0118830. eCollection 2015.

38.

Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect.

Voldsgaard A, Bager P, Garde E, Åkeson P, Leffers AM, Madsen CG, Kapel C, Roepstorff A, Thamsborg SM, Melbye M, Siebner H, Søndergaard HB, Sellebjerg F, Sørensen PS.

Mult Scler. 2015 Nov;21(13):1723-9. doi: 10.1177/1352458514568173. Epub 2015 Feb 19.

PMID:
25698173
39.

Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis.

Olsson A, Oturai DB, Sørensen PS, Oturai PS, Oturai AB.

Mult Scler. 2015 Oct;21(12):1557-65. doi: 10.1177/1352458514566417. Epub 2015 Jan 26.

PMID:
25623251
40.

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.

Marrie RA, Cohen J, Stuve O, Trojano M, Sørensen PS, Reingold S, Cutter G, Reider N.

Mult Scler. 2015 Mar;21(3):263-81. doi: 10.1177/1352458514564491. Epub 2015 Jan 26. Review.

41.

The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review.

Marrie RA, Reingold S, Cohen J, Stuve O, Trojano M, Sorensen PS, Cutter G, Reider N.

Mult Scler. 2015 Mar;21(3):305-17. doi: 10.1177/1352458514564487. Epub 2015 Jan 12. Review.

42.

Therapeutic interference with leukocyte recirculation in multiple sclerosis.

Sellebjerg F, Sørensen PS.

Eur J Neurol. 2015 Mar;22(3):434-42. doi: 10.1111/ene.12668. Epub 2015 Jan 13. Review.

PMID:
25582213
43.

The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review.

Marrie RA, Reider N, Stuve O, Trojano M, Sorensen PS, Cutter GR, Reingold SC, Cohen J.

Mult Scler. 2015 Mar;21(3):332-41. doi: 10.1177/1352458514564488. Epub 2014 Dec 23. Review.

44.

A systematic review of the incidence and prevalence of cancer in multiple sclerosis.

Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Sorensen PS, Reingold SC, Cutter G.

Mult Scler. 2015 Mar;21(3):294-304. doi: 10.1177/1352458514564489. Epub 2014 Dec 22. Review.

45.

A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis.

Marrie RA, Reider N, Cohen J, Trojano M, Sorensen PS, Cutter G, Reingold S, Stuve O.

Mult Scler. 2015 Mar;21(3):342-9. doi: 10.1177/1352458514564486. Epub 2014 Dec 22. Review.

46.

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis.

Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, Reingold S, Sorensen PS.

Mult Scler. 2015 Mar;21(3):318-31. doi: 10.1177/1352458514564485. Epub 2014 Dec 22. Review.

47.

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis.

Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G, Reingold SC, Trojano M.

Mult Scler. 2015 Mar;21(3):282-93. doi: 10.1177/1352458514564490. Epub 2014 Dec 22. Review.

48.

[Fampridine and multiple sclerosis].

Mathiesen HK, Sørensen PS.

Ugeskr Laeger. 2014 Jan 13;176(3A):V06130416. Review. Danish.

PMID:
25347174
49.

Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis.

Ratzer R, Romme Christensen J, Romme Nielsen B, Sørensen PS, Börnsen L, Sellebjerg F.

J Neuroimmunol. 2014 Nov 15;276(1-2):195-201. doi: 10.1016/j.jneuroim.2014.08.623. Epub 2014 Aug 30.

PMID:
25218212
50.

Gender effects on treatment response to interferon-beta in multiple sclerosis.

Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS.

Acta Neurol Scand. 2014 Dec;130(6):374-9. doi: 10.1111/ane.12277. Epub 2014 Sep 10.

PMID:
25208455

Supplemental Content

Loading ...
Support Center